AYTU BIOPHARMA INC (AYTU) Fundamental Analysis & Valuation

NASDAQ:AYTU • US0547548588

Current stock price

2.56 USD
0 (0%)
At close:
2.78 USD
+0.22 (+8.59%)
After Hours:

This AYTU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AYTU Profitability Analysis

1.1 Basic Checks

  • AYTU had negative earnings in the past year.
  • AYTU had a negative operating cash flow in the past year.
  • In the past 5 years AYTU always reported negative net income.
  • AYTU had a negative operating cash flow in each of the past 5 years.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • AYTU has a better Return On Assets (-20.04%) than 62.30% of its industry peers.
  • AYTU has a Return On Equity of -172.12%. This is in the lower half of the industry: AYTU underperforms 72.25% of its industry peers.
Industry RankSector Rank
ROA -20.04%
ROE -172.12%
ROIC N/A
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400 -500

1.3 Margins

  • With a decent Gross Margin value of 66.84%, AYTU is doing good in the industry, outperforming 73.82% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AYTU has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for AYTU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. AYTU Health Analysis

2.1 Basic Checks

  • AYTU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AYTU has been increased compared to 1 year ago.
  • The number of shares outstanding for AYTU has been increased compared to 5 years ago.
  • The debt/assets ratio for AYTU is higher compared to a year ago.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • AYTU has an Altman-Z score of -3.17. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.
  • AYTU has a worse Altman-Z score (-3.17) than 63.35% of its industry peers.
  • A Debt/Equity ratio of 1.34 is on the high side and indicates that AYTU has dependencies on debt financing.
  • AYTU's Debt to Equity ratio of 1.34 is on the low side compared to the rest of the industry. AYTU is outperformed by 78.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Altman-Z -3.17
ROIC/WACCN/A
WACC12.05%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • AYTU has a Current Ratio of 1.16. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
  • AYTU has a worse Current ratio (1.16) than 82.72% of its industry peers.
  • AYTU has a Quick Ratio of 1.03. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
  • AYTU's Quick ratio of 1.03 is on the low side compared to the rest of the industry. AYTU is outperformed by 81.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.03
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AYTU Growth Analysis

3.1 Past

  • The earnings per share for AYTU have decreased strongly by -206.03% in the last year.
  • The Revenue has decreased by -8.91% in the past year.
  • Measured over the past years, AYTU shows a quite strong growth in Revenue. The Revenue has been growing by 19.19% on average per year.
EPS 1Y (TTM)-206.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-303.85%
Revenue 1Y (TTM)-8.91%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-6.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 28.73% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, AYTU will show a quite strong growth in Revenue. The Revenue will grow by 14.87% on average per year.
EPS Next Y33.48%
EPS Next 2Y33.95%
EPS Next 3Y28.73%
EPS Next 5YN/A
Revenue Next Year-18.12%
Revenue Next 2Y8.49%
Revenue Next 3Y10.97%
Revenue Next 5Y14.87%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

1

4. AYTU Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AYTU. In the last year negative earnings were reported.
  • Also next year AYTU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • AYTU's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AYTU is cheaper than 99.48% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.39
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AYTU's earnings are expected to grow with 28.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.95%
EPS Next 3Y28.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AYTU Dividend Analysis

5.1 Amount

  • No dividends for AYTU!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AYTU Fundamentals: All Metrics, Ratios and Statistics

AYTU BIOPHARMA INC

NASDAQ:AYTU (4/15/2026, 11:41:30 AM)

After market: 2.78 +0.22 (+8.59%)

2.56

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-03
Earnings (Next)05-12
Inst Owners35.17%
Inst Owner Change0%
Ins Owners8.41%
Ins Owner Change0%
Market Cap27.47M
Revenue(TTM)62.64M
Net Income(TTM)-24.44M
Analysts82.22
Price Target9.86 (285.16%)
Short Float %5.15%
Short Ratio9.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)58.97%
Min EPS beat(2)-71.57%
Max EPS beat(2)189.51%
EPS beat(4)2
Avg EPS beat(4)-1841.93%
Min EPS beat(4)-7706.78%
Max EPS beat(4)221.11%
EPS beat(8)5
Avg EPS beat(8)-898.77%
EPS beat(12)7
Avg EPS beat(12)-899.55%
EPS beat(16)9
Avg EPS beat(16)-691.59%
Revenue beat(2)2
Avg Revenue beat(2)15.98%
Min Revenue beat(2)9.83%
Max Revenue beat(2)22.12%
Revenue beat(4)3
Avg Revenue beat(4)11.6%
Min Revenue beat(4)-17.2%
Max Revenue beat(4)31.67%
Revenue beat(8)6
Avg Revenue beat(8)7.77%
Revenue beat(12)8
Avg Revenue beat(12)2.67%
Revenue beat(16)10
Avg Revenue beat(16)2.66%
PT rev (1m)3.57%
PT rev (3m)3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.51%
EPS NY rev (1m)0%
EPS NY rev (3m)-44.74%
Revenue NQ rev (1m)-1.76%
Revenue NQ rev (3m)-1.76%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)2.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.44
P/FCF N/A
P/OCF N/A
P/B 1.93
P/tB N/A
EV/EBITDA 2.39
EPS(TTM)-3.55
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS5.84
BVpS1.32
TBVpS-2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -20.04%
ROE -172.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.84%
FCFM N/A
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Debt/EBITDA 4.91
Cap/Depr 72.18%
Cap/Sales 4.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.03
Altman-Z -3.17
F-Score3
WACC12.05%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-206.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-303.85%
EPS Next Y33.48%
EPS Next 2Y33.95%
EPS Next 3Y28.73%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.91%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-6.51%
Revenue Next Year-18.12%
Revenue Next 2Y8.49%
Revenue Next 3Y10.97%
Revenue Next 5Y14.87%
EBIT growth 1Y90.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-235.36%
EBIT Next 3Y76.95%
EBIT Next 5YN/A
FCF growth 1Y-160.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-109.73%
OCF growth 3YN/A
OCF growth 5YN/A

AYTU BIOPHARMA INC / AYTU Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AYTU BIOPHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to AYTU.


Can you provide the valuation status for AYTU BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to AYTU BIOPHARMA INC (AYTU). This can be considered as Overvalued.


What is the profitability of AYTU stock?

AYTU BIOPHARMA INC (AYTU) has a profitability rating of 1 / 10.